Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer

Medical Oncology

Volumn 28, Issue 3, 2011, Pages 716-725

  Nurgalieva, Zhannat ^a   Liu, Chih Chin ^a   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anemia; Bone marrow toxicity; Breast cancer; Chemotherapy; Ovarian cancer

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

AGED; ANEMIA; APLASTIC ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG INDUCED DISEASE; FEMALE; HUMAN; INCIDENCE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEER PROGRAM; THROMBOCYTOPENIA;

EID: 80052483718     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9512-5     Document Type: Article

References (40)

1. RV Gardner C Lerner CM Astle DE Harrison 1993 Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay Cancer Chemother Pharmacol 32 450 454 8258193 10.1007/BF00685889 1:CAS:528:DyaK2cXht1eqtbg%3D
2. MJ Hassett A James O'Malley JR Pakes JP Newhouse CC Earle 2006 Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer J Natl Cancer Inst 98 1108 1117 16912263 10.1093/jnci/djj305
3. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
4. Y Wang V Probin D Zhou 2006 Cancer therapy-induced residual bone marrow injury: mechanisms of induction and implication for therapy Curr Cancer Ther Rev 2 271 279 19936034 10.2174/157339406777934717 1:CAS:528:DC%2BD28Xos12jtbs%3D
5. HB Muss DA Berry C Cirrincione DR Budman IC Henderson ML Citron L Norton EP Winer CA Hudis Cancer and Leukemia Group B Experience 2007 Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience J Clin Oncol 25 24 3699 3704 17704418 10.1200/JCO.2007.10.9710 1:CAS:528:DC%2BD2sXhtVeqt7fP
6. Gale RP. Myelosuppressive effects of antineoplastic chemotherapy. In: Testa NG, Gale RP, editors. Hematopoiesis: long-term effects of chemotherapy and radiation. New York: Marcel Dekker, Inc.; 1988. p. 63-73.
7. NG Testa JH Hendry G Molineux 1985 Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy Anticancer Res 5 101 110 3888044 1:STN:280:DyaL2M7pslKrsg%3D%3D
8. Young NS, Abkowitz JL, Luzzatto L. New insights into the pathophysiology of acquired cytopenias. Hematology 2000;18-38.
9. RJ Hartsock EB Smith CS Petty 1965 Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. A study made from 177 cases of sudden death examined by necropsy Am J Clin Pathol 43 326 331 14275849 1:STN:280:DyaF2M%2FotVCitw%3D%3D
10. RV Gardner R Begue E McKinnon 2001 The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on primitive hematopoietic stem cell (PHSC) function and numbers, after chemotherapy Exp Hematol 29 1053 1059 11532345 10.1016/S0301-472X(01)00685-3 1:CAS:528:DC%2BD3MXmt1KrtLo%3D
11. R van Os S Robinson T Sheridan JM Mislow D Dawes PM Mauch 1998 Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents Blood 92 1950 1956 9731052
12. J Crawford DC Dale NM Kuderer E Culakova MS Poniewierski D Wolff GH Lyman 2008 Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice J Natl Compr Cancer Netw 6 2 109 118
13. GH Lyman DC Dale J Crawford 2003 Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J Clin Oncol 21 4524 4531 14673039 10.1200/JCO.2003.05.002
14. S Vadhan-Raj 2009 Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents Semin Hematol 46 1 Suppl 2 S26 S32 19245931 10.1053/j.seminhematol.2008.12.007 1:CAS:528:DC%2BD1MXktFGhsrg%3D Links
15. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda: National Cancer Institute; 2008.
16. AL Potosky GF Riley JD Lubitz, et al. 1993 Potential for cancer related health services research using a linked Medicare-tumor registry database Med Care 31 732 748 8336512 10.1097/00005650-199308000-00006 1:STN:280: DyaK3szivF2hsA%3D%3D
17. National Cancer Institute: The SEER Program Code Manual (revised ed). Bethesda, MD, National Cancer Institute, 1994, NIH publication 94-1999.
18. Health Care Financing Administration. Data user reference guide (DURG). Baltimore: Health Care Financing Administration; 2000.
19. U.S. Public Health Services. International classification of diseases, 9th revision. Clinical modification. 5th ed. Los Angeles: Practice Management Information Corporation; 1996.
20. American Medical Association. Physicians' current procedural terminology: CPT 94. Chicago: American Medical Association; 1993.
21. Health Care Financing Administration. HCFA common procedure coding system (HCPCS): national level II Medicare codes. Los Angeles: Practice Management Information Corporation; 1994.
22. Health Care Financing Administration. HCFA data dictionary: revenue center codes. Baltimore: Health Care Financing Administration; 1999.
23. JL Warren LC Harlan A Fahey, et al. 2002 Utility of the SEER-Medicare data to identify chemotherapy use Med Care 40 8 Suppl IV55 IV61
24. ME Charlson P Pompei KL Ales, et al. 1987 A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 373 383 3558716 10.1016/0021-9681(87)90171-8 1:STN:280: DyaL2s7ms1GnsQ%3D%3D
25. PS Romano LL Roos JG Jollis 1993 Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives J Clin Epidemiol 46 1075 1079 8410092 10.1016/0895-4356(93)90103-8 1:STN:280: DyaK2c%2FhsFWrsw%3D%3D
26. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary: SAS Institute Inc; 1997.
27. M Shayne E Culakova MS Poniewierski D Wolff DC Dale J Crawford GH Lyman 2007 Dose intensity and bone marrow toxicity in older cancer patients receiving systemic chemotherapy Cancer 110 1611 1620 17705197 10.1002/cncr.22939
28. JC Marsh 1976 The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: a review Cancer Res 36 1853 1882 773531 1:CAS:528:DyaE28XksVSnu70%3D
29. W Dempke A Von Poblozki A Grothey HJ Schmoll 2000 Human hematopoietic growth factors: old lessons and new perspectives Anticancer Res 20 5155 5164 11326688 1:CAS:528:DC%2BD3MXjsVWlu7Y%3D
30. S Neben S Hellman M Montgomery J Ferrara P Mauch S Hemman 1993 Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents Exp Hematol 21 156 162 8435103 1:CAS:528:DyaK2cXivV2mt7g%3D
31. JG Kuhn 2002 Chemotherapy-associated hematopoietic toxicity Am J Health Syst Pharm 59 15 Suppl 4 S4 S7 12166034
32. Steensma DP. Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol 2008;26(7).
33. JL Spivak 2005 The anaemia of cancer: death by a thousand cuts Nat Rev Cancer 5 7 543 555 15965494 10.1038/nrc1648 1:CAS:528:DC%2BD2MXmtFOnsL0%3D
34. A Hurria K Brogan KS Panageas C Pearce L Norton A Jakubowski M Zauderer J Howard C Hudis 2005 Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy Breast Cancer Res Treat 92 151 156 15986124 10.1007/s10549-005-1410-8 1:CAS:528:DC%2BD2MXls1agsLs%3D
35. HB Muss DA Berry CT Cirrincione 2009 Adjuvant chemotherapy in older women with early stage breast cancer NEJM 360 20 2055 2062 10.1056/NEJMoa0810266
36. SM Lichtman JA Skirvin 2000 Pharmacology of antineoplastic agents in older cancer patients Oncology 14 1743 1763 11204376 1:STN:280: DC%2BD3M7nvVCjtQ%3D%3D
37. NK Ibrahim DK Frye AU Buzdar, et al. 1996 Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome Arch Intern Med 156 882 888 8774207 10.1001/archinte.156.8.882 1:CAS:528: DyaK28Xis1Slurc%3D
38. GG Kimmick HB Muss 2001 Systemic therapy for older women with breast cancer Oncology 15 3 280 299 11301828 1:STN:280:DC%2BD3MvjsFantw%3D%3D
39. B Begaud Y Moride P Tubert-Bitter A Chaslerie F Haramburu 1994 False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol 38 5 401 404 7893579 1:STN:280:DyaK2M3gtVOktg%3D%3D
40. DW Kaufman S Shapiro 2000 Epidemiological assessment of drug-induced disease Lancet 356 9238 1339 1343 11073036 10.1016/S0140-6736(00)02826-9 1:STN:280:DC%2BD3crhsVSrtg%3D%3D